Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study. (4th July 2022)

• Record Type: Journal Article
• Authors: Torres, T.; Paiva-Lopes, M. J.; Gonçalo, M.; Claro, C.; Oliveira, M.; Gomes, J.; Vieira, A. P.; Amoedo, P.; Alpalhão, M.; Nogueira, M.; Santiago, F.; Henrique, M.; Amaro, C.; Esteves, T.; Alves, J.; Cerejeira, D.; Mendes-Bastos, P.; Pestana, M.; Ramos, L.; Rocha, J.; Carvalho, R.; Teixeira, L.; Selores, M.; Mota, A.; Filipe, P.
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 5(2022)
• Page Start: 2554
• Page End: 2559
• Publication Date: 2022-07-04
• Subjects: Atopic dermatitis -- treatment -- biologics -- dupilumab; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2022.2035309
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Introduction: Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients' quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in patients aged 6 or older. Methods: This is a nationwide, multicenter, retrospective, 48-week study designed by the Portuguese Group of AD to assess real-world efficacy and safety of dupilumab for the treatment of AD. Results: A total of 169 patients were enrolled, with a mean disease duration of 22.75 (±11.98) years. The percentage of patients achieving an improvement of at least 75% in Eczema Area and Severity Index (EASI) compared to baseline (EASI75 response) at weeks 12 and 48 was 67.6% and 74.1%, respectively. In the same timepoints, 25.0% and 44.1% achieved an EASI90 response. Patient-reported outcome measures also improved throughout the study period. Regarding safety, 32.0% of the patients developed adverse events, with conjunctivitis (26.6%), persistent facial erythema (4.7%), and arthritis/arthralgia (3.6%) as the more frequently reported. Conclusion: Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.